Mainz Biomed NV, a molecular genetics diagnostic company, announced the pricing of a $4.0 million follow-on offering of 2,000,000 units, each consisting of an ordinary share and Series A and B warrants. The units are priced at $2.00 each. The Series A and B warrants are exercisable at $2.00 per share, with the Series A warrants expiring five years from issuance and Series B warrants expiring either 30 days after eAArly Detect 2 study results or one year from issuance. Additionally, a Warrant Amendment Agreement reduces the strike prices of previously issued warrants to $2.00. Maxim Group LLC is the sole placement agent, with the offering expected to close around May 21, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.